Annual SG&A
$146.09 M
+$8.35 M+6.06%
31 December 2023
Summary:
Xeris Biopharma Holdings annual selling, general & administrative expenses is currently $146.09 million, with the most recent change of +$8.35 million (+6.06%) on 31 December 2023. During the last 3 years, it has risen by +$72.36 million (+98.14%). XERS annual SG&A is now at all-time high.XERS Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$44.97 M
+$4.98 M+12.44%
30 September 2024
Summary:
Xeris Biopharma Holdings quarterly selling, general & administrative expenses is currently $44.97 million, with the most recent change of +$4.98 million (+12.44%) on 30 September 2024. Over the past year, it has increased by +$7.68 million (+20.60%). XERS quarterly SG&A is now -17.00% below its all-time high of $54.18 million, reached on 31 December 2021.XERS Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$2.57 B
-$63.11 M-2.52%
30 September 2024
Summary:
Xeris Biopharma Holdings TTM selling, general & administrative expenses is currently -$2.57 billion, with the most recent change of -$63.11 million (-2.52%) on 30 September 2024. Over the past year, it has dropped by -$2.71 billion (-1899.21%). XERS TTM SG&A is now -4143.27% below its all-time high of $160.91 million, reached on 30 September 2024.XERS TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
XERS Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +6.1% | +20.6% | -1899.2% |
| 3 y3 years | +98.1% | +69.5% | -2971.2% |
| 5 y5 years | +592.0% | +202.3% | -5126.6% |
XERS Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +98.1% | -17.0% | +69.5% | -73.0% | at low |
| 5 y | 5 years | at high | +592.0% | -17.0% | +202.3% | -289.5% | at low |
| alltime | all time | at high | +3498.4% | -17.0% | +3253.4% | -4143.3% | at low |
Xeris Biopharma Holdings Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $44.97 M(+12.4%) | $160.91 M(+5.0%) |
| June 2024 | - | $39.99 M(+4.2%) | $153.23 M(+1.6%) |
| Mar 2024 | - | $38.38 M(+2.2%) | $150.87 M(+3.3%) |
| Dec 2023 | $146.09 M(+6.1%) | $37.57 M(+0.8%) | $146.09 M(+2.2%) |
| Sept 2023 | - | $37.29 M(-0.9%) | $142.88 M(+2.0%) |
| June 2023 | - | $37.63 M(+12.0%) | $140.09 M(+3.4%) |
| Mar 2023 | - | $33.60 M(-2.2%) | $135.44 M(-1.7%) |
| Dec 2022 | $137.75 M(+9.6%) | $34.36 M(-0.4%) | $137.75 M(-12.6%) |
| Sept 2022 | - | $34.49 M(+4.6%) | $157.57 M(+5.3%) |
| June 2022 | - | $32.98 M(-8.2%) | $149.61 M(+5.0%) |
| Mar 2022 | - | $35.91 M(-33.7%) | $142.55 M(+13.4%) |
| Dec 2021 | $125.72 M(+70.5%) | $54.18 M(+104.2%) | $125.72 M(+40.4%) |
| Sept 2021 | - | $26.54 M(+2.3%) | $89.54 M(+12.6%) |
| June 2021 | - | $25.93 M(+35.9%) | $79.49 M(+11.6%) |
| Mar 2021 | - | $19.08 M(+6.0%) | $71.20 M(-3.4%) |
| Dec 2020 | $73.73 M | $18.00 M(+9.2%) | $73.73 M(-3.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | $16.48 M(-6.6%) | $76.38 M(+2.1%) |
| June 2020 | - | $17.64 M(-18.3%) | $74.77 M(+3.6%) |
| Mar 2020 | - | $21.61 M(+4.7%) | $72.15 M(+14.4%) |
| Dec 2019 | $63.06 M(+198.7%) | $20.64 M(+38.8%) | $63.06 M(+23.3%) |
| Sept 2019 | - | $14.88 M(-1.0%) | $51.14 M(+25.0%) |
| June 2019 | - | $15.02 M(+20.0%) | $40.92 M(+34.6%) |
| Mar 2019 | - | $12.52 M(+43.5%) | $30.39 M(+43.9%) |
| Dec 2018 | $21.11 M(+163.4%) | $8.72 M(+87.6%) | $21.11 M(+36.3%) |
| Sept 2018 | - | $4.65 M(+3.4%) | $15.49 M(+20.5%) |
| June 2018 | - | $4.50 M(+38.9%) | $12.85 M(+29.7%) |
| Mar 2018 | - | $3.24 M(+4.6%) | $9.91 M(+23.7%) |
| Dec 2017 | $8.02 M(+97.4%) | $3.10 M(+53.6%) | $8.02 M(+63.0%) |
| Sept 2017 | - | $2.02 M(+29.4%) | $4.92 M(+69.6%) |
| June 2017 | - | $1.56 M(+16.3%) | $2.90 M(+116.3%) |
| Mar 2017 | - | $1.34 M | $1.34 M |
| Dec 2016 | $4.06 M | - | - |
FAQ
- What is Xeris Biopharma Holdings annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings annual SG&A year-on-year change?
- What is Xeris Biopharma Holdings quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings quarterly SG&A year-on-year change?
- What is Xeris Biopharma Holdings TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings TTM SG&A year-on-year change?
What is Xeris Biopharma Holdings annual selling, general & administrative expenses?
The current annual SG&A of XERS is $146.09 M
What is the all time high annual SG&A for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high annual selling, general & administrative expenses is $146.09 M
What is Xeris Biopharma Holdings annual SG&A year-on-year change?
Over the past year, XERS annual selling, general & administrative expenses has changed by +$8.35 M (+6.06%)
What is Xeris Biopharma Holdings quarterly selling, general & administrative expenses?
The current quarterly SG&A of XERS is $44.97 M
What is the all time high quarterly SG&A for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high quarterly selling, general & administrative expenses is $54.18 M
What is Xeris Biopharma Holdings quarterly SG&A year-on-year change?
Over the past year, XERS quarterly selling, general & administrative expenses has changed by +$7.68 M (+20.60%)
What is Xeris Biopharma Holdings TTM selling, general & administrative expenses?
The current TTM SG&A of XERS is -$2.57 B
What is the all time high TTM SG&A for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high TTM selling, general & administrative expenses is $160.91 M
What is Xeris Biopharma Holdings TTM SG&A year-on-year change?
Over the past year, XERS TTM selling, general & administrative expenses has changed by -$2.71 B (-1899.21%)